B. Metzler seel. Sohn & Co. AG Buys 69 Shares of Cencora, Inc. (NYSE:COR)

B. Metzler seel. Sohn & Co. AG lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 0.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,389 shares of the company’s stock after acquiring an additional 69 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Cencora were worth $1,660,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. C M Bidwell & Associates Ltd. increased its stake in shares of Cencora by 28.8% in the fourth quarter. C M Bidwell & Associates Ltd. now owns 1,509 shares of the company’s stock worth $339,000 after purchasing an additional 337 shares in the last quarter. FSB Premier Wealth Management Inc. increased its stake in Cencora by 8.6% in the 4th quarter. FSB Premier Wealth Management Inc. now owns 2,281 shares of the company’s stock worth $512,000 after buying an additional 180 shares in the last quarter. O Shaughnessy Asset Management LLC raised its holdings in Cencora by 16.7% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 52,965 shares of the company’s stock valued at $11,900,000 after acquiring an additional 7,597 shares during the period. United Bank lifted its position in shares of Cencora by 15.8% in the fourth quarter. United Bank now owns 6,487 shares of the company’s stock valued at $1,457,000 after acquiring an additional 886 shares in the last quarter. Finally, RWA Wealth Partners LLC grew its position in shares of Cencora by 1.8% during the fourth quarter. RWA Wealth Partners LLC now owns 33,983 shares of the company’s stock worth $7,635,000 after purchasing an additional 586 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Price Performance

COR opened at $279.60 on Thursday. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The business has a fifty day moving average of $255.83 and a 200 day moving average of $242.06. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $280.70. The stock has a market cap of $54.22 billion, a P/E ratio of 39.77, a PEG ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.79%. Cencora’s payout ratio is currently 31.29%.

Insider Activity

In related news, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the transaction, the chairman now owns 317,913 shares in the company, valued at $85,680,732.63. This trade represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on COR shares. JPMorgan Chase & Co. boosted their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Wells Fargo & Company upped their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. Mizuho started coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target on the stock. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Finally, Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $280.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.